Skip to main content

Advertisement

Table 1 Patients' characteristics

From: Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

  Total CTC positive in % Pvalue
Overall 245 122 50%  
ER status 244 122 50 0.26
Negative 74 33 45  
Positive 170 89 52  
PR status 244 122 50 0.51
Negative 99 47 48  
Positive 145 75 52  
HER2 status 245 122 123 0.15
Negative1 138 76 55  
Positive2 75 31 41  
Unknown3 32 15 47  
Metastatic site 245 122 50 0.07
Visceral 96 39 41  
Bone 35 14 40  
Both 114 69 61  
Extent of metastatic disease 245 122 50 0.03
One site 84 34 41  
Multiple sites 161 88 55  
Therapeutic setting 244 122 50  
1st-line 94 48 51 0.48
2nd-line 64 28 44  
3rd-line or more 86 46 54  
CAIX 245 (253) 4 122 50  
≤506 ng/ml 157 (163) 65 41 0.00
> 506 ng/ml 88 (90) 57 65  
TIMP-1 245 (253) 4 122 50  
≤454 ng/ml 179 (183) 77 43 0.00
> 454 ng/ml 66 (70) 45 68  
  1. 1 Immunohistochemistry score: 0/+1 or fluorescence in situ hybridization negative, 2 ICH score: +3 or fluorescence in situ hybridization positive
  2. 3 not determined or ICH score +2 and fluorescence in situ hybridization not performed
  3. 4 in 9 patients CTC could not be determined
  4. CAIX, carbonic anhydrase IX; CTC, circulating tumor cell; ER, estrogen receptor; HER, human epidermal growth factor receptor; PR, progesterone receptor; TIMP, tissue inhibitor of metalloproteinase.